JLJ648 |
カタログ番号GC78898
One-Click Copy Product Info
|
JLJ648 is a Gag-Pol dimerizer with antiviral activity.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, JLJ648 (3 days) inhibits HIV-1 replication in MT-2 cells with an EC50 of 1.6 nM[1]. JLJ648 shows low cytotoxicity in MT-2 and THP-1 cells (CC50>100 μM) and a CC50 of 22.9 μM in primary CD4+ T cells[1]. JLJ648 (17 h) promotes the homodimerization of recombinant HIV-1 RT p66 subunit with an EC50 of 95 nM[1]. JLJ648 (3-4 h) induces HIV protease-dependent pyroptosis in THP-1 clone14 cells and HIV-infected primary CD4+ T cells, with an EC50 of 86 nM[1]. JLJ648 (50 μM, 12 h) binds to HIV-1 RT p66 to form two oligomeric structures, subunits in catalytic/structural conformations and "infinity knot"-shaped homotetramer[1].
References:
[1]. Hollander K, et al. Mechanistic basis for a novel dual-function Gag-Pol dimerizer potentiating CARD8 inflammasome activation and clearance of HIV-infected cells. NPJ Drug Discov. 2025;2(1):22.
| Cas No. | SDF | ||
| Formula | C23H17N3O3S | M.Wt | 415.46 |
| 溶解度 | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.407 mL | 12.0349 mL | 24.0697 mL |
| 5 mM | 481.4 μL | 2.407 mL | 4.8139 mL |
| 10 mM | 240.7 μL | 1.2035 mL | 2.407 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)